Efficacy of teneligliptin with metformin in Type 2 diabetes mellitus patients

Abstract

Background: Type 2 diabetes mellitus (T2DM) is rapidly growing epidemic in India. It is well known that the level of glycemia is associated with complications of T2DM. Aims and Objectives: The objective of this study was to assess the efficacy of teneligliptin with metformin in T2DM patients. Materials and Methods: This was a randomized, open-label, comparative study carried out for the duration of 1 year in Gandhi Medical College, Secunderabad, Telangana. One hundred patients inadequately controlled on metformin 1 g alone; having glycated hemoglobin (HbA1c) >6.5, fasting blood sugar (FBS) >110 mg/dl, and postprandial blood sugar (PPBS) >180 mg/dl attending the outpatient Department of General Medicine, Kamineni Institute of Medical Sciences. All patients were randomly allotted into two groups. Fifty patients were started with teneligliptin along with metformin. Fifty patients were started with placebo while continuing with metformin. The endpoint was change in fasting plasma glucose (FPG), postprandial blood glucose (PPBH), and HbA1c levels at 24 weeks as compared to the baseline levels in both groups. The efficacy was assessed by measuring the change in the FPG, PPBH, and HbA1c levels after 24 weeks of treatment. Data were presented in the form of statistical tables and charts. SPSS software version 20 was used for statistical analysis. Results: After 24 weeks of treatment with teneligliptin and metformin, case subjects had significant decrease in FBS, PPBS, and HbA1c. There was no significant change in BMI, blood pressure, and lipid parameters in both groups after study. All patients tolerated drugs well without any side effects. Conclusions: The combination of teneligliptin with metformin was associated with clinically significant reduction in HbA1C. This study depicted that teneligliptin can be an effective alternative to other drugs for add on therapy to the patients who are inadequately controlled with metformin alone.